Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.
Hodgkin Lymphoma|Relapsed or Refractory Hodgkin Lymphoma
DRUG: pembrolizumab|DRUG: gemcitabine|DRUG: vinorelbine|DRUG: liposomal doxorubicin|PROCEDURE: Stem cell mobilization and collection
Complete response rate (part 1), Response to pembrolizumab-GVD will be assessed using the RECIL criteria., 2 years
Evaluate the 2-year PFS rate (part 2), Only patients who receive the Pembrolizumab maintenance regime will be considered evaluable for 2-year PFS and OS rates., 2 years
The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.